Cancer combo trial pulled before it even started
NCT ID NCT07137390
First seen Jan 28, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This study planned to test two drugs, regorafenib and lorigerlimab, given before surgery to people with colorectal cancer that had spread only to their lungs. The goal was to see if the combination was safe and could help shrink tumors. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regorafenib and lorigerlimab
What this could lead to
If it had worked, this combination might have offered a new treatment option before surgery for people with colorectal cancer that spread only to the lungs.
What could go wrong
The trial was withdrawn before enrolling anyone, so no results are available. The approach was still very early-stage and unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.